Isatuximab vs SCTC21C

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: CD38 · full Multiple Myeloma pipeline

Isatuximab

Marketed by Sanofi

Approved in Multiple Myelomamonoclonal antibody
Partial signal

NCT02990338 · Phase 3 · completed

Participants were randomized 1:1 to isatuximab plus pomalidomide and dexamethasone or pomalidomide and dexamethasone alone, but the study was open-label rather than double-blind. The primary clinical endpoint, progression-free survival, was met: median survival was 11.53 versus 6.47 months, with a hazard ratio of 0.596 and p=0.0005.

Next expected readout: November 2026 · NCT06517017 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279) (met)

Result source: NCT02990338

SCTC21C

Developed by Sinocelltech Group Ltd.

Phase 3 in Multiple Myelomabiologic (registry-typed, subtype undisclosed)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07297329 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIsatuximabSCTC21C
PFS, median11.5 vs 6.5vs Pomalidomide + Dexamethasonen 154NCT02990338
7 other results
—Trial running · NCT07297329
OS, median24.6 vs 17.7vs Pomalidomide + Dexamethasonen 154NCT02990338
1 other result
—Trial running · NCT07297329
ORR60.4% vs 35.3%vs Pomalidomide + Dexamethasonen 154NCT02990338
7 other results
—Trial running · NCT07297329
VGPR or better31.8% vs 8.5%vs Pomalidomide + Dexamethasonen 154NCT02990338
1 other result
  • 72.6% vs 56.1% n 179 · Phase 3 · secondary NCT03275285
—Trial running · NCT07297329
MRD negativity—Not posted · NCT05804032—Trial running · NCT07297329

PFS, median

Isatuximab
11.5 vs 6.5vs Pomalidomide + Dexamethasonen 154NCT02990338
7 other results
SCTC21C
—Trial running · NCT07297329

OS, median

Isatuximab
24.6 vs 17.7vs Pomalidomide + Dexamethasonen 154NCT02990338
1 other result
SCTC21C
—Trial running · NCT07297329

ORR

Isatuximab
60.4% vs 35.3%vs Pomalidomide + Dexamethasonen 154NCT02990338
7 other results
SCTC21C
—Trial running · NCT07297329

VGPR or better

Isatuximab
31.8% vs 8.5%vs Pomalidomide + Dexamethasonen 154NCT02990338
1 other result
  • 72.6% vs 56.1% n 179 · Phase 3 · secondary NCT03275285
SCTC21C
—Trial running · NCT07297329

MRD negativity

Isatuximab
—Not posted · NCT05804032
SCTC21C
—Trial running · NCT07297329
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SCTC21C: no structured comparison results are available for Multiple Myeloma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Isatuximab: 4 of 4 rows · SCTC21C: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIsatuximab
Dropout rate
n/a: no completion milestonea
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
show 8 more results
n/a: no completion milestone
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
—Phase 1: Isatuximab+Cemiplimab Q2W
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 2: Isatuximab
NCT03194867 · Phase 1/2 · registry result, not featured evidence
2.8%Phase 2: Isatuximab + CemiplimabQ2
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2:Isatuximab + CemiplimabQ4W
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone20 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone10 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
14.3%a
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
show 8 more results
16.2%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
—Phase 1: Isatuximab+Cemiplimab Q2W
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2: Isatuximab
NCT03194867 · Phase 1/2 · registry result, not featured evidence
—Phase 2: Isatuximab + CemiplimabQ2
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2:Isatuximab + CemiplimabQ4W
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
40%20 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
0%10 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
Serious AEs
73.7%a
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
show 8 more results
72.9%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
33.3%Phase 1: Isatuximab+Cemiplimab Q2W
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
51.5%Phase 2: Isatuximab
NCT03194867 · Phase 1/2 · registry result, not featured evidence
45.9%Phase 2: Isatuximab + CemiplimabQ2
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
60%Phase 2:Isatuximab + CemiplimabQ4W
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
40%20 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
39.3%20 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
33.3%10 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
a
neutropenia 50.7%
upper respiratory tract infection 34.9%
infusion related reaction 34.2%
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
show 8 more results
infusion related reaction 45.2%
upper respiratory tract infection 41.2%
diarrhoea 40.7%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
infusion related reaction 66.7%
back pain 33.3%
chills 33.3%
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
infusion related reaction 54.5%
diarrhoea 18.2%
arthralgia 15.2%
NCT03194867 · Phase 1/2 · registry result, not featured evidence
infusion related reaction 40.5%
fatigue 21.6%
back pain 18.9%
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
infusion related reaction 42.9%
diarrhoea 20%
upper respiratory tract infection 20%
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
20 mg/kg
vomiting 40%
anaemia 20%
fatigue 20%
NCT02812706 · Phase 1/2 · registry result, not featured evidence
20 mg/kg
infusion related reaction 42.9%
nasopharyngitis 21.4%
pyrexia 21.4%
NCT02812706 · Phase 1/2 · registry result, not featured evidence
10 mg/kg
infusion related reaction 66.7%
nasopharyngitis 66.7%
back pain 33.3%
NCT02812706 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 7 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Isatuximab

PFS 11.53 vs 6.47 Pomalidomide + Dexamethasone months
time to event · months
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
show 5 more results
7.491 vs 3.745 Pomalidomide + Dexamethasone months
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
NA vs 19.15 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
NA vs 20.27 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
35.65 vs 19.15 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
41.66 vs 20.76 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
ORR 60.4% (n=154) vs 35.3% (n=153) Pomalidomide + Dexamethasone
responder rate · % of participants
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
86.6% (n=179) vs 82.9% (n=123) Carfilzomib + Dexamethasone
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
VGPR or Better 31.8% (n=154) vs 8.5% (n=153) Pomalidomide + Dexamethasone
responder rate · % of participants
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
72.6% (n=179) vs 56.1% (n=123) Carfilzomib + Dexamethasone
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Clinical Benefit 66.9% (n=154) vs 46.4% (n=153) Pomalidomide + Dexamethasone
responder rate · % of participants
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
Overall Survival 24.57 vs 17.71 Pomalidomide + Dexamethasone months
time to event · months
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
NA vs 50.6 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Time to Progression 12.71 vs 7.75 Pomalidomide + Dexamethasone months
time to event · months
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
NA vs 20.27 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Duration of Response 13.27 vs 11.07 Pomalidomide + Dexamethasone months
time to event · months
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
NA vs NA Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Time to Response 1.94 vs 3.02 Pomalidomide + Dexamethasone months
time to event · months
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
VGPR or Better With MRD Negativity 29.6% (n=179) vs 13% (n=123) Carfilzomib + Dexamethasone
responder rate · % of participants
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
33.5% (n=179) vs 13.8% (n=123) Carfilzomib + Dexamethasone
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Complete 44.1% (n=179) vs 28.5% (n=123) Carfilzomib + Dexamethasone
responder rate · % of participants
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Complete Response With MRD Negativity 26.3% (n=179) vs 12.2% (n=123) Carfilzomib + Dexamethasone
responder rate · % of participants
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
PFS2 47.18 vs 35.58 Carfilzomib + Dexamethasone months
time to event · months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
47.18 vs 32.36 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3

+ 8 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Isatuximab's landscape · SCTC21C's landscape